Hematology & Oncology

Our division participates in multiple cancer-related clinical trials that offer novel treatment modalities for eligible patients. Many clinical trials are still open for patient enrollment and include studies investigating efficacies of various treatment regimens for breast, lung, and colon cancer. Some of the clinical trails are listed below. For further information on these trials or for eligibility, please contact Maria Rapuzzi, RN, MPA, Research manager, Oncology Division.

Fellowship Program Director 
Frank Forte, MD - Division Director 

Key Clinical Faculty 
Quan Dai, MD
Meekoo Dhar, MD
Philip Friscia, MD 
Shilpi Gupta, MBBS
Marcel Odaimi, MD - Chairman of Oncology Performance Improvement, Chairman of Tumor Board
Terenig Terjanian, MD - Director Hematology/Oncology-South Site, Chairman of Cancer Committee   

List of Clinical Trials Open for Accrual:

  • Colon Cancer:

    • Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer, PI: Dr. Forte 

    • A Phase III Trial or Irinotecan/ 5-FU/ Leucovorin or Oxaliplatin/ 5-FU/Leucovorin with Bevacizumano Cextuximab (C225) For Patients With Treated Metastatic Adenocarcinom the Colon or Rectum, PI: Dr. Odaimi 
  • Lung Cancer:

    • A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuzimab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC), PI: Dr. Friscia

    • ECOG-5508 Randomized Phase III study of Maintenance Therapy with Bevacizumab, Premetrexed or a combination of Bevacizumab and Premetrexed following carboplatin, paclitaxel and bevacizumab for advanced non-squamous NSCLC, PI: Dr. Friscia
  • Metastatic Cancer:
    (Breast, Prostate, Multiple Myeloma)

    • A Randomized Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zaledronic Acid in Metastatic Cancer, PI: Dr. Forte
  • Renal Cancer:

    • A Randomized Double Blinded, Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma, PI: Dr. Forte

    • Randomized Phase III Trial comparing Everolimus plus Placebo Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment with Tyrosine Kinase Inhibitors (CALGB 90802), PI: Dr. Forte


  • Invited Presentations:

    • Maarouf O, Waked A, Geara A, Khoueiry G, AbiRached J, Ayoub I, Terjanian T, Lafferty J, Dunne E, Smith M, El Sayegh S. An analysis of the diet of hemodialysis patients during a dialysis specific FFQ. - Presented at the New York American College of Physicians' Upstate Scientific Meeting on April 10, 2010.
    • Mourad M, Aoun N, Baz W, Friscia P. Humoral hypercalcemia of malignancy (HHM) in association with mucoepidermoid carcinoma of the parotid gland. - Presented at the New York American College of Physicians' Upstate Scientific Meeting on April 10, 20